fetoprotein BI 2536 in gr He is over 50 in the H Half of the patients. On the other side was the toxicity Tsprofil not be ignored Ssigbar, but still acceptable. Antiangiogenic agents HCC is known that good vascularization and tumor angiogenesis plays a r Important role in the pathogenesis. Therefore, the angiogenesis and growth factors. Contribute to its regulation, the main objective of this type of cancer, at least in theory, In addition to sorafenib, which t is an anti-proliferative activity Both antineoangiogenic and has locks of the MAP kinase pathway, many other drugs have been studied in HCC. That’m Ren bevacizumab, a monoclonal antique Different body against VEGF and sunitinib brivanib and vatalanib Cediranib, small molecule inhibitors of kinases. No activity T or even safety data brivanib, vatalanib Cediranib and are not yet available because the relevant ongoing clinical trials.
A first test CX-4945 of bevacizumab, J Updated annually from 2005 to 2007 and completely Constantly ver ffentlicht In 2008, clearly showed that bevacizumab is safe when at a dose of 5 mg and 10 kg for patients with locally unresectable HCC administered, but adequate liver function and have no residual varicose veins of the feeder hre high risk of bleeding. Overall, these results show a positive effect of this monoclonal Body, the. On the natural course of the disease, the DCR is 80, and the median TTP of more than 6 months But one of the main results and painful, this process is an increase of 11 t the risk of bleeding Can be fatal, the feeder veins Hre. The results of the efficacy and toxicity of t Bevacizumab were subsequently Fran end of a small phase best Justified ease Study. Another recent study has shown bevacizumab to be active and well tolerated Possible when administered intra-arterially kg in a dose of 5 mg. 10 patients, 2 complete remission for 4 months, w While 6 others had. Partial remission and 2 more stable disease 6 mo Seven of the 10 patients showed a serological response, such as a decrease in the values of a1 fetoprotein gr He defined 50, compared to the initial values.
These encouraging results have of course a best Confirmation stock series of patients. We have already mentioned the promising combination with erlotinib Reconciled, but stressed that bevacizumab was also be combined, especially in small phase Trials with chemotherapeutics with some, albeit small, t activity Against HCC, n Namely capecitabine and oxaliplatin or gemcitabine or. One study looked at the combination of capecitabine, oxaliplatin and bevacizumab. Of the 30 patients who had this treatment, 11 achieved a partial response and 78 had stable disease by. Up to a total of 89 DCR The median PFS was 5.4 months with 70 and 40 PFS at 3 and 6 months. Regarding tolerance, 33 patients Grade 3 2 or 3 neuropathy with oxaliplatin and 11 degrees February capecitabine-induced hand-foot syndrome induced. One patient had intestinal